Get the Stockscreener App
5.22
1.51%
-0.08
After Hours:
5.18
-0.04
-0.77%
Fibrogen Inc stock is traded at $5.22, with a volume of 59,644.
It is down -1.51% in the last 24 hours and down -35.05% over the past month.
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
See More
Previous Close:
$5.30
Open:
$5.29
24h Volume:
59,644
Relative Volume:
1.50
Market Cap:
$31.22M
Revenue:
$147.75M
Net Income/Loss:
$-284.23M
P/E Ratio:
-1.7816
EPS:
-2.93
Net Cash Flow:
$-317.54M
1W Performance:
-9.22%
1M Performance:
-35.05%
6M Performance:
-64.00%
1Y Performance:
-79.73%
1-Day Range:
$5.18
$5.4617
1-Week Range:
$5.18
$5.8467
52-Week Range:
$4.50
$38.25
Fibrogen Inc Stock (FGEN) Company Profile
Name
Fibrogen Inc
Sector
Industry
Phone
415-978-1200
Address
350 BAY STREET, SAN FRANCISCO, CA
Compare FGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FGEN
Fibrogen Inc
|
5.22 | 31.22M | 147.75M | -284.23M | -317.54M | -2.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Fibrogen Inc Stock (FGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-26-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-26-23 | Downgrade | Stifel | Buy → Hold |
| Jun-26-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-02-23 | Upgrade | Stifel | Hold → Buy |
| Jan-31-23 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-05-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-22-21 | Downgrade | Goldman | Neutral → Sell |
| Aug-20-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-16-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-16-21 | Downgrade | Stifel | Buy → Hold |
| Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-07-21 | Downgrade | Mizuho | Buy → Neutral |
| Mar-31-21 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-02-21 | Downgrade | Jefferies | Buy → Hold |
| Feb-01-21 | Initiated | H.C. Wainwright | Buy |
| Oct-26-20 | Initiated | Raymond James | Underperform |
| Jul-10-20 | Resumed | Stifel | Buy |
| May-01-20 | Initiated | Cowen | Market Perform |
| Apr-27-20 | Initiated | BofA/Merrill | Neutral |
| May-29-19 | Resumed | Goldman | Neutral |
| May-10-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-12-19 | Initiated | Piper Jaffray | Neutral |
| Feb-11-19 | Resumed | Stifel | Buy |
| Dec-19-18 | Upgrade | Citigroup | Neutral → Buy |
| Aug-08-17 | Reiterated | Leerink Partners | Outperform |
| Aug-08-17 | Reiterated | Stifel | Buy |
| Jul-21-17 | Downgrade | Goldman | Buy → Neutral |
| Jul-11-17 | Initiated | Jefferies | Buy |
| Feb-11-16 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-21-16 | Initiated | Credit Suisse | Neutral |
| Dec-04-15 | Initiated | Citigroup | Buy |
| Sep-23-15 | Initiated | Lake Street | Hold |
| Jul-29-15 | Initiated | Citigroup | Buy |
| Jul-20-15 | Upgrade | Goldman | Neutral → Buy |
| Dec-09-14 | Initiated | Stifel | Buy |
View All
Fibrogen Inc Stock (FGEN) Latest News
FibroGen (FGEN) Trading Halted Pending News Release | FGEN Stock News - GuruFocus
FibroGen Enters New Agreement with HiFiBiO - TipRanks
Fibrogen IncOn June 12 Enters Termination, Asset Transfer And License Agreement With Hifibio - MarketScreener
FibroGen (FGEN) Announces 1-for-25 Reverse Stock Split | FGEN St - GuruFocus
FibroGen to implement 1-for-25 reverse stock split; shares down 15% - MSN
Adobe, FibroGen And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Adobe, RH And 3 Stocks To Watch Heading Into FridayAdobe (NASDAQ:ADBE), FibroGen (NASDAQ:FGEN) - Benzinga
FibroGen Announces 1-for-25 Reverse Stock Split | FGEN Stock New - GuruFocus
FibroGen Announces Reverse Stock Split Effective June 16 - TipRanks
FibroGen to Implement 1-for-25 Reverse Stock Split - marketscreener.com
FibroGen To Implement 1-for-25 Reverse Stock Split - Nasdaq
FibroGen, Inc. Announces 1-for-25 Reverse Stock Split Effective June 16, 2025 - Nasdaq
Fibrogen Announces 1-For-25 Reverse Stock Split - marketscreener.com
FibroGen Announces 1-for-25 Reverse Stock Split - GlobeNewswire
FibroGen's Massive 1-for-25 Reverse Split Cuts 101M Shares to 4MWhat Investors Must Know - Stock Titan
Millennium Management LLC Lowers Stock Position in FibroGen, Inc. (NASDAQ:FGEN) - Defense World
FibroGen expands board with biotech veteran Kauffman By Investing.com - Investing.com South Africa
FibroGen expands board with biotech veteran Kauffman - Investing.com Australia
FibroGen Amends Financing Agreement for Flexibility - TipRanks
FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors | FGEN Stock News - GuruFocus
Fibrogen Appoints Michael Kauffman To Its Board Of Directors - marketscreener.com
FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors - GlobeNewswire
FibroGen Strengthens Board with Velcade Developer: Key Move for Pipeline Advancement - Stock Titan
Squarepoint Ops LLC Takes Position in FibroGen, Inc. (NASDAQ:FGEN) - Defense World
Two Sigma Advisers LP Has $465,000 Position in FibroGen, Inc. (NASDAQ:FGEN) - Defense World
FibroGen, Inc. (NASDAQ:FGEN) Shares Sold by Price T Rowe Associates Inc. MD - Defense World
FibroGen (NASDAQ:FGEN) Now Covered by Analysts at StockNews.com - Defense World
FibroGen outlines $185M China divestiture and extended cash runway into 2027 while advancing prostate cancer pipeline - MSN
FibroGen Q1 2025 slides: China sale to extend cash runway amid revenue decline By Investing.com - Investing.com South Africa
FibroGen First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
FibroGen Q1 2025 slides: China sale to extend cash runway amid revenue decline - Investing.com Australia
HC Wainwright Has Negative Outlook for FibroGen Q2 Earnings - Defense World
FibroGen’s Earnings Call: Strategic Gains Amid Revenue Woes - TipRanks
FibroGen (NASDAQ:FGEN) Earns Buy Rating from HC Wainwright - Defense World
FibroGen (FGEN) Boosts Sale Proceeds from Chinese Division - GuruFocus
FibroGen (FGEN) Receives Reaffirmed Buy Rating from HC Wainwrigh - GuruFocus
FibroGen, Inc. (NASDAQ:FGEN) Q1 2025 Earnings Call Transcript - Insider Monkey
FibroGen Inc earnings beat by $0.15, revenue fell short of estimates - Investing.com UK
FibroGen Inc (FGEN) Q1 2025 Earnings Call Highlights: Strategic Moves and Cost Management Amid ... - Yahoo Finance
FibroGen Inc (FGEN) Q1 2025 Earnings Call Highlights: Strategic Moves and Cost Management Amid Revenue Decline - GuruFocus
FibroGen Reports Q1 2025 Earnings and Strategic Updates - TipRanks
Earnings call transcript: FibroGen Q1 2025 sees revenue drop, stock rises - Investing.com Canada
FibroGen Q1 2025 Earnings Call Transcript - MarketBeat
FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
FibroGen Inc reports results for the quarter ended March 31Earnings Summary - TradingView
FibroGen Inc Reports Q1 2025 Earnings: Revenue Surpasses Estimates at $2.7M, EPS Misses with $0.16 Loss - GuruFocus
FibroGen Inc Reports Q1 2025 Earnings: Revenue Surpasses Estimat - GuruFocus
FibroGen: Q1 Earnings Snapshot - San Antonio Express-News
FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
FIBROGEN INC SEC 10-Q Report - TradingView
Fibrogen Inc Stock (FGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Fibrogen Inc Stock (FGEN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Schoeneck James A | Director |
Mar 20 '25 |
Buy |
0.35 |
250,000 |
88,000 |
323,722 |
| Schoeneck James A | Director |
Mar 21 '25 |
Buy |
0.34 |
50,000 |
17,040 |
373,722 |
1.11%
1.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):